 Tamara Perry
Concepts (237)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 35 | 2025 | 314 | 10.110 |
Why?
| | Food Hypersensitivity | 12 | 2025 | 100 | 3.470 |
Why?
| | Telemedicine | 11 | 2025 | 492 | 3.230 |
Why?
| | Hypersensitivity | 10 | 2023 | 81 | 3.030 |
Why?
| | Allergens | 17 | 2021 | 141 | 2.800 |
Why?
| | Child | 46 | 2025 | 7147 | 1.560 |
Why?
| | Schools | 5 | 2023 | 177 | 1.450 |
Why?
| | Anti-Asthmatic Agents | 5 | 2025 | 33 | 1.420 |
Why?
| | Rural Population | 8 | 2022 | 571 | 1.350 |
Why?
| | Patient Education as Topic | 2 | 2025 | 318 | 1.190 |
Why?
| | Environmental Exposure | 8 | 2023 | 214 | 1.150 |
Why?
| | School Health Services | 4 | 2023 | 52 | 1.060 |
Why?
| | Health Services Accessibility | 5 | 2025 | 438 | 1.020 |
Why?
| | Spirometry | 4 | 2025 | 33 | 1.020 |
Why?
| | Adolescent | 26 | 2025 | 6681 | 0.970 |
Why?
| | Humans | 70 | 2025 | 52114 | 0.950 |
Why?
| | Dermatitis, Atopic | 3 | 2023 | 40 | 0.920 |
Why?
| | Healthcare Disparities | 5 | 2022 | 296 | 0.900 |
Why?
| | Peanut Hypersensitivity | 8 | 2019 | 92 | 0.820 |
Why?
| | Air Pollution | 1 | 2023 | 46 | 0.760 |
Why?
| | Metformin | 1 | 2023 | 80 | 0.760 |
Why?
| | Delivery of Health Care | 3 | 2022 | 318 | 0.750 |
Why?
| | Air Pollutants | 1 | 2023 | 72 | 0.740 |
Why?
| | Health Status Disparities | 3 | 2021 | 216 | 0.730 |
Why?
| | Quality of Life | 5 | 2025 | 878 | 0.720 |
Why?
| | Air Pollution, Indoor | 4 | 2014 | 27 | 0.690 |
Why?
| | Immunoglobulin E | 8 | 2019 | 92 | 0.680 |
Why?
| | Desensitization, Immunologic | 7 | 2020 | 107 | 0.620 |
Why?
| | Adrenal Cortex Hormones | 3 | 2025 | 114 | 0.620 |
Why?
| | Skin Tests | 9 | 2019 | 58 | 0.610 |
Why?
| | Physicians | 1 | 2022 | 235 | 0.580 |
Why?
| | Arkansas | 13 | 2024 | 2016 | 0.550 |
Why?
| | Male | 34 | 2025 | 26652 | 0.540 |
Why?
| | Female | 34 | 2025 | 28055 | 0.520 |
Why?
| | Health Communication | 1 | 2017 | 23 | 0.510 |
Why?
| | Poverty | 2 | 2023 | 220 | 0.500 |
Why?
| | Child, Preschool | 22 | 2025 | 4001 | 0.480 |
Why?
| | Urban Population | 4 | 2018 | 161 | 0.480 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 2 | 2025 | 5 | 0.470 |
Why?
| | Reminder Systems | 1 | 2015 | 28 | 0.460 |
Why?
| | United States | 11 | 2025 | 5168 | 0.460 |
Why?
| | Housing | 2 | 2006 | 48 | 0.450 |
Why?
| | Self Efficacy | 3 | 2025 | 134 | 0.450 |
Why?
| | Cockroaches | 1 | 2014 | 2 | 0.430 |
Why?
| | Self Care | 1 | 2015 | 135 | 0.430 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2014 | 16 | 0.430 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2025 | 608 | 0.360 |
Why?
| | Caregivers | 4 | 2019 | 236 | 0.360 |
Why?
| | Rural Health | 2 | 2009 | 88 | 0.360 |
Why?
| | Medicaid | 2 | 2024 | 263 | 0.350 |
Why?
| | Food Supply | 2 | 2023 | 92 | 0.330 |
Why?
| | Anaphylaxis | 3 | 2016 | 69 | 0.320 |
Why?
| | Allergy and Immunology | 2 | 2024 | 19 | 0.320 |
Why?
| | Socioeconomic Factors | 3 | 2023 | 603 | 0.300 |
Why?
| | Cats | 2 | 2006 | 73 | 0.290 |
Why?
| | Epinephrine | 4 | 2016 | 92 | 0.280 |
Why?
| | Egg Hypersensitivity | 3 | 2020 | 27 | 0.280 |
Why?
| | Immunization | 3 | 2017 | 68 | 0.260 |
Why?
| | Suburban Population | 1 | 2006 | 7 | 0.260 |
Why?
| | Dust | 3 | 2014 | 23 | 0.240 |
Why?
| | Young Adult | 3 | 2025 | 4307 | 0.240 |
Why?
| | Muscarinic Antagonists | 1 | 2025 | 24 | 0.230 |
Why?
| | Patient Selection | 2 | 2018 | 265 | 0.230 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2004 | 8 | 0.220 |
Why?
| | Risk Factors | 8 | 2024 | 3922 | 0.220 |
Why?
| | Respiratory System | 1 | 2004 | 28 | 0.220 |
Why?
| | Quinolines | 1 | 2004 | 43 | 0.220 |
Why?
| | Acetates | 1 | 2004 | 51 | 0.220 |
Why?
| | Patient Satisfaction | 2 | 2017 | 283 | 0.220 |
Why?
| | Minority Groups | 2 | 2022 | 132 | 0.210 |
Why?
| | Diagnostic Errors | 1 | 2004 | 69 | 0.210 |
Why?
| | Avoidance Learning | 1 | 2003 | 16 | 0.210 |
Why?
| | Prevalence | 5 | 2019 | 1013 | 0.210 |
Why?
| | Risk Reduction Behavior | 1 | 2003 | 58 | 0.210 |
Why?
| | Vitamin D Deficiency | 1 | 2023 | 46 | 0.200 |
Why?
| | Poverty Areas | 1 | 2003 | 43 | 0.200 |
Why?
| | Emergency Service, Hospital | 5 | 2024 | 515 | 0.190 |
Why?
| | Administration, Oral | 8 | 2020 | 453 | 0.190 |
Why?
| | Cross-Sectional Studies | 5 | 2025 | 1665 | 0.190 |
Why?
| | Educational Status | 1 | 2023 | 227 | 0.190 |
Why?
| | Morbidity | 3 | 2023 | 140 | 0.190 |
Why?
| | Infant | 11 | 2024 | 3660 | 0.180 |
Why?
| | Virus Diseases | 1 | 2022 | 47 | 0.180 |
Why?
| | Trust | 1 | 2022 | 60 | 0.180 |
Why?
| | Lung Diseases | 1 | 2022 | 83 | 0.170 |
Why?
| | Disease Progression | 1 | 2023 | 866 | 0.170 |
Why?
| | Parents | 1 | 2003 | 334 | 0.170 |
Why?
| | Forced Expiratory Volume | 3 | 2025 | 52 | 0.160 |
Why?
| | Absenteeism | 1 | 2019 | 17 | 0.160 |
Why?
| | Sympathomimetics | 2 | 2016 | 21 | 0.150 |
Why?
| | Severity of Illness Index | 4 | 2025 | 1035 | 0.150 |
Why?
| | Adult | 6 | 2025 | 14095 | 0.150 |
Why?
| | Antigens, Plant | 3 | 2013 | 16 | 0.150 |
Why?
| | Patient Dropouts | 1 | 2018 | 51 | 0.140 |
Why?
| | Glycoproteins | 3 | 2013 | 122 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 83 | 0.140 |
Why?
| | Basophils | 2 | 2015 | 14 | 0.140 |
Why?
| | Eosinophils | 1 | 2017 | 40 | 0.130 |
Why?
| | Community Health Services | 1 | 2018 | 102 | 0.130 |
Why?
| | Quality Assurance, Health Care | 1 | 2018 | 147 | 0.130 |
Why?
| | Health Literacy | 1 | 2019 | 131 | 0.130 |
Why?
| | Animals | 5 | 2014 | 13332 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2025 | 6610 | 0.130 |
Why?
| | Eosinophilic Esophagitis | 1 | 2017 | 43 | 0.130 |
Why?
| | Esophagus | 1 | 2017 | 83 | 0.130 |
Why?
| | Models, Statistical | 1 | 2018 | 231 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 49 | 0.130 |
Why?
| | Quality Improvement | 1 | 2018 | 223 | 0.120 |
Why?
| | Basophil Degranulation Test | 1 | 2015 | 3 | 0.120 |
Why?
| | Hospitalization | 3 | 2024 | 739 | 0.110 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2015 | 21 | 0.110 |
Why?
| | Administration, Inhalation | 2 | 2025 | 111 | 0.110 |
Why?
| | Advisory Committees | 1 | 2014 | 72 | 0.110 |
Why?
| | Plant Proteins | 3 | 2015 | 70 | 0.110 |
Why?
| | Meningitis, Pneumococcal | 1 | 2013 | 7 | 0.110 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 10 | 0.100 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 399 | 0.100 |
Why?
| | Lactose Intolerance | 1 | 2013 | 1 | 0.100 |
Why?
| | Manikins | 1 | 2013 | 32 | 0.100 |
Why?
| | Emergency Medicine | 1 | 2013 | 49 | 0.100 |
Why?
| | Mycobacterium fortuitum | 1 | 2013 | 6 | 0.100 |
Why?
| | Macrolides | 1 | 2013 | 17 | 0.100 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 63 | 0.100 |
Why?
| | Clarithromycin | 1 | 2013 | 38 | 0.100 |
Why?
| | Methicillin | 1 | 2012 | 10 | 0.090 |
Why?
| | Clindamycin | 1 | 2012 | 14 | 0.090 |
Why?
| | House Calls | 1 | 2012 | 26 | 0.090 |
Why?
| | Odds Ratio | 2 | 2019 | 564 | 0.090 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 76 | 0.090 |
Why?
| | Prospective Studies | 4 | 2023 | 2424 | 0.090 |
Why?
| | Influenza Vaccines | 1 | 2011 | 34 | 0.090 |
Why?
| | Influenza, Human | 1 | 2011 | 85 | 0.080 |
Why?
| | Pediatrics | 1 | 2013 | 291 | 0.080 |
Why?
| | Risk | 2 | 2016 | 312 | 0.080 |
Why?
| | Bronchitis | 1 | 2010 | 10 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1031 | 0.080 |
Why?
| | Demography | 1 | 2010 | 92 | 0.080 |
Why?
| | Mice | 2 | 2014 | 5877 | 0.080 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 272 | 0.080 |
Why?
| | Staphylococcus aureus | 1 | 2012 | 312 | 0.080 |
Why?
| | Immune Tolerance | 2 | 2011 | 91 | 0.080 |
Why?
| | Immunotherapy | 1 | 2011 | 240 | 0.070 |
Why?
| | Treatment Outcome | 4 | 2025 | 5456 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2013 | 718 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2282 | 0.070 |
Why?
| | Recurrence | 1 | 2010 | 680 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 196 | 0.070 |
Why?
| | New York | 2 | 2018 | 49 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2013 | 328 | 0.070 |
Why?
| | Treatment Failure | 2 | 2020 | 122 | 0.070 |
Why?
| | Animals, Domestic | 1 | 2006 | 6 | 0.060 |
Why?
| | Antigens, Dermatophagoides | 1 | 2006 | 4 | 0.060 |
Why?
| | Maryland | 1 | 2006 | 31 | 0.060 |
Why?
| | Dogs | 1 | 2006 | 182 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 796 | 0.060 |
Why?
| | Vital Capacity | 1 | 2025 | 17 | 0.060 |
Why?
| | Adrenergic beta-Agonists | 1 | 2025 | 42 | 0.060 |
Why?
| | Reference Values | 1 | 2025 | 313 | 0.060 |
Why?
| | Sulfides | 1 | 2004 | 29 | 0.060 |
Why?
| | Cyclopropanes | 1 | 2004 | 27 | 0.060 |
Why?
| | Nebulizers and Vaporizers | 1 | 2025 | 58 | 0.060 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2004 | 3 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2019 | 195 | 0.050 |
Why?
| | False Positive Reactions | 1 | 2004 | 63 | 0.050 |
Why?
| | Detergents | 1 | 2004 | 15 | 0.050 |
Why?
| | Area Under Curve | 1 | 2004 | 182 | 0.050 |
Why?
| | Hand Disinfection | 1 | 2004 | 9 | 0.050 |
Why?
| | Body Mass Index | 1 | 2007 | 699 | 0.050 |
Why?
| | Apoptosis | 1 | 2009 | 1117 | 0.050 |
Why?
| | Cholecalciferol | 1 | 2023 | 22 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2004 | 238 | 0.050 |
Why?
| | Vitamins | 1 | 2023 | 65 | 0.050 |
Why?
| | Office Visits | 1 | 2003 | 44 | 0.050 |
Why?
| | Vitamin D | 1 | 2023 | 90 | 0.050 |
Why?
| | Nutritional Status | 1 | 2023 | 142 | 0.050 |
Why?
| | Prognosis | 2 | 2020 | 2093 | 0.050 |
Why?
| | Hospitals | 1 | 2024 | 180 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 494 | 0.050 |
Why?
| | Respiratory Sounds | 1 | 2022 | 50 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2022 | 89 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2004 | 939 | 0.040 |
Why?
| | Health Promotion | 1 | 2023 | 270 | 0.040 |
Why?
| | Risk Management | 1 | 2021 | 30 | 0.040 |
Why?
| | Food | 1 | 2021 | 67 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2019 | 2859 | 0.040 |
Why?
| | Cooking | 1 | 2020 | 16 | 0.040 |
Why?
| | Smoking | 1 | 2003 | 516 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2023 | 467 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 267 | 0.040 |
Why?
| | Tertiary Healthcare | 1 | 2019 | 15 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 250 | 0.040 |
Why?
| | Lung | 1 | 2022 | 488 | 0.040 |
Why?
| | Urban Health | 1 | 2018 | 31 | 0.040 |
Why?
| | Videoconferencing | 1 | 2018 | 38 | 0.030 |
Why?
| | Preventive Health Services | 1 | 2018 | 52 | 0.030 |
Why?
| | Rats | 1 | 2003 | 3146 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 63 | 0.030 |
Why?
| | Seasons | 1 | 2017 | 92 | 0.030 |
Why?
| | Histamine Antagonists | 1 | 2016 | 17 | 0.030 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 86 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 185 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 57 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2018 | 234 | 0.030 |
Why?
| | Interprofessional Relations | 1 | 2017 | 90 | 0.030 |
Why?
| | Egg Proteins | 1 | 2015 | 18 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 132 | 0.030 |
Why?
| | Emergency Medical Services | 1 | 2016 | 112 | 0.030 |
Why?
| | Middle Aged | 2 | 2015 | 13028 | 0.030 |
Why?
| | Milk Proteins | 1 | 2015 | 77 | 0.030 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2015 | 21 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2016 | 141 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2017 | 742 | 0.030 |
Why?
| | Pregnancy | 1 | 2022 | 2658 | 0.030 |
Why?
| | 2S Albumins, Plant | 1 | 2013 | 7 | 0.030 |
Why?
| | Emergency Treatment | 1 | 2013 | 29 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2013 | 61 | 0.030 |
Why?
| | Amikacin | 1 | 2013 | 17 | 0.030 |
Why?
| | Azithromycin | 1 | 2013 | 25 | 0.030 |
Why?
| | Urticaria | 1 | 2013 | 19 | 0.020 |
Why?
| | Equipment Design | 1 | 2013 | 290 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2012 | 36 | 0.020 |
Why?
| | Milk Hypersensitivity | 1 | 2012 | 19 | 0.020 |
Why?
| | Hospitals, University | 1 | 2012 | 74 | 0.020 |
Why?
| | Patient Care Team | 1 | 2013 | 271 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 1568 | 0.020 |
Why?
| | Regression Analysis | 1 | 2012 | 399 | 0.020 |
Why?
| | Health Surveys | 1 | 2012 | 238 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 270 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2012 | 239 | 0.020 |
Why?
| | Clinical Competence | 1 | 2013 | 396 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2009 | 69 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 83 | 0.020 |
Why?
| | Social Class | 1 | 2009 | 95 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 343 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2007 | 80 | 0.020 |
Why?
| | Rural Health Services | 1 | 2009 | 169 | 0.020 |
Why?
| | Cytokines | 1 | 2009 | 621 | 0.020 |
Why?
|
|
Perry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|